Remember meForgot password?
    Log in with Twitter
| Press Release

Jamaica's Ministry of Health Approves United Cannabis Corporation's Prana CBD-Infused Water as a Registered Medicinal Cannabis Product

The Company's Hemp Aromatherapy Roll-On, Capsules, and Sublingual Drops Are Already Registered with The Ministry of Health

DENVER, CO / ACCESSWIRE / October 12, 2017 / United Cannabis Corporation (OTCQB: CNAB) (the "Company" or "United Cannabis") today announced that Jamaica's Ministry of Health has registered its Prana CBD-Infused Water as a medicinal cannabis product. The Prana Water will be manufactured and distributed by the Company's Jamaican subsidiary, Cannabinoid Research & Development Limited ("CRD").

CRD has already begun preliminary work to initiate production of other United Cannabis products in Jamaica, including its Prana P5 Hemp Bio Nutrient Capsules, Aromatherapy Roll-On, and Sublingual Drops.

This approval strengthens the Company's competitive advantage by giving it access to other markets, including Canada, Australia, and New Zealand, which are approved for the purchase of hemp-based products from Jamaica.

The Prana Collection is at the center of United Cannabis' proprietary cannabis-centric therapies and patients have found the hemp-derived Prana CBD-infused formulations effective in providing relief from the symptoms of arthritis, neuropathy, acute pain, joint aches, muscle tension, muscle spasms, muscle recovery, migraines, and various skin conditions.

Earnest Blackmon, Chief Executive Officer of United Cannabis, commented on the announcement saying, "Acceptance of medical cannabis has been considerably faster in Jamaica than the United States, and we established CRD so that we could be a part of the commercialization process. Our production facility is state-of-the-art and we expect our CBD-infused water, as well as our other approved products, will be ready for distribution by the end of the month."

About Cannabinoid Research & Development Limited

Cannabinoid Research & Development (CRD), a subsidiary of United Cannabis, is a Jamaican based corporation pursuing local licensing to advance the use of medical cannabis therapies through biomedical research and development for the nutraceutical industry. CRD focuses on genetic restoration, cannabinoid isolation techniques, scientific research, educational programs, and promotes domestic job opportunities. John Sayers, along with Kenyama Brown, local Jamaican directors and executives of CRD, coupled with Jamaican partners specializing in agricultural science and plant-based medicine, will help United Cannabis implement Sayer's 40 years of agricultural methodologies into localized educational curriculums, job training programs, and help with integration of localized products.

About United Cannabis Corporation

United Cannabis Corporation is a biotechnology company dedicated to the development of phyto-therapeutic based products supported by patented technologies for the pharmaceutical, medical, and industrial markets. The Company has long advocated the application of cannabinoids for medical applications and is building a platform for designing targeted therapies to increase the quality of life for patients around the world. The Company's products are patent protected, first in class medicines with applications to a global market. United Cannabis trades on the OTCQB under the symbol CNAB.

For further information, please visit

Phone: 303-386-7321

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

SOURCE: United Cannabis Corporation